IMARC Group has recently released a new research study “intravenous (IV) ibuprofen market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028”, offers a detailed analysis of the market drivers, segmentation, growth opportunities, trends, and competitive landscape to understand the current and future market scenarios.
The global intravenous (IV) ibuprofen market size reached US$ 6.3 Billion in 2022. Looking forward, IMARC Group expects the market to reach a value of US$ 10.2 Billion by 2028, exhibiting a growth rate (CAGR) of 7.78% during 2023-2028.
Ibuprofen is associated with the nonsteroidal anti-inflammatory drug (NSAID) class that is used to treat inflammation, pain, fever, etc. It inhibits cyclooxygenase COZ-1 and COX-2 enzymes that are required for the synthesis of prostaglandins (PG). Intravenous (IV) ibuprofen is utilized alone or with other medicines to relieve mild to severe discomfort. It is injected directly into the vein to block the production of certain natural substances that cause inflammation. Intravenous (IV) ibuprofen aids in reducing narcotic analgesic requirements and lower pain levels with an excellent safety profile. It also assists in improving pain control and minimizing the usage of opioid drugs in orthopedic and abdominal surgeries and fever.
Request and get a sample brochure for free: https://www.imarcgroup.com/intravenous-ibuprofen-market/requestsample
Market Trends
The rising prevalence of arthritis, cardiovascular diseases (CVDs), cancer, etc., and the expanding geriatric population across countries, are among the key factors stimulating the intravenous (IV) ibuprofen market. Moreover, hectic working schedules and unhealthy lifestyles, as well as a consequent decline in physical activity and proper nutrition, have led to increasing incidences of chronic diseases, which is positively influencing the global market.
Besides this, the widespread adoption of intravenous (IV) ibuprofen to manage rheumatoid disorders, mild to moderate pain, fever, dysmenorrhea, osteoarthritis, etc., is acting as another significant growth-inducing factor. Furthermore, it is also used to treat mild fever, dental pain, gastrointestinal pain, ductus arteriosus in pediatrics, etc., which is propelling the market growth. Apart from this, continuous improvements in the healthcare infrastructures and the growing consumer health consciousness are expected to fuel the intravenous (IV) ibuprofen market over the forecasted period.
For the competitor segment, the report includes global key players of the Intravenous (IV) Ibuprofen Market
- Cumberland Pharmaceuticals Inc.
- Hyloris Pharmaceuticals SA
- Recordati Rare Diseases Inc.
- VALMOR Laboratories CA
- and Xgen Pharmaceuticals Djb Inc.
The report segmentation is as follows:
The report has segmented the market into the following categories:
Breakup by Product Dose:
- 100 Mg Dose
- 200 Mg Dose
- 400 Mg Dose
- 800 Mg Dose
Breakup by Indication:
- Pain/Inflammatory
- Fever
Breakup by Age Group:
- Pediatrics
- Adults
Regional Insights:
- Asia Pacific
- North America
- Europe
- Middle East and Africa
- Latin America
On the geographical front, Asia Pacific enjoys the leading position in the market. This can be attributed to the rising establishment of international companies in the region, on account of low manufacturing costs and cheap labor.
Ask An Analyst For Free Custmization:https://www.imarcgroup.com/request?type=report&id=6440&flag=C
If you want latest primary and secondary data (2022-2027) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours of receiving full payment.
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic, and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology, and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Services Private Limited.
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Email: [email protected]
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 |
Africa and Europe :- +44-702-409-7331 |
Asia: +91-120-433-0800, +91-120-433-0800
